HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jian-Mei Li Selected Research

pterostilbene

6/2022Corrigendum to "Pterostilbene and allopurinol reduce fructose-induced podocyte oxidative stress and inflammation via microRNA-377" [Free Radic. Biol. Med. 83 (2015) 214-26].
1/2019Pterostilbene prevents hepatocyte epithelial-mesenchymal transition in fructose-induced liver fibrosis through suppressing miR-34a/Sirt1/p53 and TGF-β1/Smads signalling.
6/2015Pterostilbene and allopurinol reduce fructose-induced podocyte oxidative stress and inflammation via microRNA-377.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jian-Mei Li Research Topics

Disease

10Inflammation (Inflammations)
06/2022 - 05/2004
10Insulin Resistance
01/2017 - 05/2004
7Cognitive Dysfunction
07/2020 - 07/2006
6Obesity
01/2020 - 04/2005
6Metabolic Syndrome (Dysmetabolic Syndrome X)
12/2015 - 12/2007
5Hyperuricemia
02/2022 - 10/2009
5Neoplasms (Cancer)
01/2022 - 08/2011
5Stroke (Strokes)
08/2009 - 02/2007
5Atherosclerosis
02/2008 - 10/2004
4Cardiovascular Diseases (Cardiovascular Disease)
01/2022 - 01/2004
4Cardiomegaly (Heart Hypertrophy)
08/2021 - 10/2002
4Vascular Diseases (Vascular Disease)
01/2017 - 01/2003
4Fatty Liver
05/2010 - 05/2004
3Neuroinflammatory Diseases
04/2022 - 11/2016
3Nasopharyngeal Carcinoma
09/2021 - 01/2018
3Heart Failure
08/2021 - 10/2002
3Neurodegenerative Diseases (Neurodegenerative Disease)
07/2020 - 09/2014
3Alzheimer Disease (Alzheimer's Disease)
07/2020 - 10/2008
3Body Weight (Weight, Body)
11/2019 - 04/2008
3Type 2 Diabetes Mellitus (MODY)
01/2013 - 10/2004
3Vascular System Injuries
02/2004 - 10/2002
2Mental Disorders (Mental Disorder)
04/2022 - 04/2008
2Hypertension (High Blood Pressure)
01/2022 - 11/2004
2Pathologic Processes
07/2020 - 06/2015
2Brain Injuries (Brain Injury)
07/2020 - 09/2008
2Gliosis
01/2019 - 02/2015
2Fibrosis (Cirrhosis)
01/2019 - 05/2004
2Hyperinsulinism (Hyperinsulinemia)
01/2013 - 02/2008
2Ischemia
09/2008 - 11/2004
2Glucose Intolerance
12/2007 - 12/2006
2Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
07/2007 - 07/2006
2Hypertrophy
11/2004 - 10/2002
2Hyperlipidemias (Hyperlipidemia)
11/2004 - 08/2003
2Vascular Remodeling
02/2004 - 10/2002
1Aortic Aneurysm (Aneurysm, Aortic)
01/2022
1Thyroid Neoplasms (Thyroid Cancer)
01/2022
1Fatigue
09/2021

Drug/Important Bio-Agent (IBA)

13FructoseIBA
06/2022 - 10/2009
11NADPH Oxidases (NAD(P)H oxidase)IBA
08/2021 - 10/2002
10Angiotensin IIIBA
01/2022 - 10/2003
9Reactive Oxygen Species (Oxygen Radicals)IBA
08/2021 - 10/2002
6Insulin (Novolin)FDA Link
12/2015 - 05/2004
6olmesartanIBA
12/2007 - 10/2002
4Betaine (C.B.B.)FDA Link
01/2016 - 01/2014
4AntioxidantsIBA
06/2015 - 11/2004
4CytokinesIBA
02/2015 - 08/2003
4PPAR gammaIBA
10/2008 - 05/2004
3pterostilbeneIBA
06/2022 - 06/2015
3Allopurinol (Remid)FDA LinkGeneric
06/2022 - 10/2009
3Biomarkers (Surrogate Marker)IBA
01/2022 - 09/2014
3Pharmaceutical PreparationsIBA
01/2022 - 11/2013
3acetovanillone (apocynin)IBA
01/2020 - 11/2013
3Small Interfering RNA (siRNA)IBA
01/2019 - 07/2006
3InflammasomesIBA
01/2019 - 06/2015
3CurcuminIBA
11/2016 - 05/2010
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2016 - 02/2004
3Glucose (Dextrose)FDA LinkGeneric
06/2016 - 08/2003
34- ethoxymethylene- 2- phenyl- 2- oxazoline- 5- one (phOx)IBA
06/2016 - 10/2002
3Insulin ReceptorIBA
12/2015 - 11/2007
3EnzymesIBA
09/2014 - 08/2003
3Calcium Channel Blockers (Blockers, Calcium Channel)IBA
02/2008 - 02/2004
3Superoxides (Superoxide)IBA
02/2008 - 02/2004
3Messenger RNA (mRNA)IBA
09/2007 - 02/2005
3azelnidipineIBA
12/2006 - 02/2004
2MicroRNAs (MicroRNA)IBA
06/2022 - 12/2015
2Volatile Fatty AcidsIBA
04/2022 - 01/2019
2horse chestnut seedIBA
02/2022 - 09/2011
2CoumarinsIBA
02/2022 - 09/2011
2Oxidoreductases (Dehydrogenase)IBA
01/2022 - 10/2002
2Oxidants (Oxidizing Agents)IBA
08/2021 - 11/2004
2Therapeutic UsesIBA
01/2020 - 09/2011
21,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium SaltIBA
01/2020 - 01/2009
2NF-kappa B (NF-kB)IBA
01/2016 - 02/2005
2LipidsIBA
01/2016 - 03/2014
2Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
12/2015 - 02/2004
2Non-Receptor Type 1 Protein Tyrosine PhosphataseIBA
12/2015 - 05/2010
2LeptinIBA
01/2013 - 05/2010
2QuercetinIBA
01/2013 - 10/2009
2Uric Acid (Urate)IBA
09/2011 - 10/2009
210,10'-dimethyl-9,9'-biacridinium (Lucigenin)IBA
01/2009 - 10/2002
2NADP (NADPH)IBA
01/2009 - 10/2002
2Angiotensin Receptor AntagonistsIBA
12/2007 - 12/2006
2CholesterolIBA
12/2007 - 01/2003
2Nitric Oxide (Nitrogen Monoxide)FDA Link
11/2007 - 10/2004
2Valsartan (Vals)FDA Link
07/2006 - 05/2004
2ApolipoproteinsIBA
07/2005 - 04/2005
2Estrogens (Estrogen)FDA Link
04/2005 - 10/2002
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
11/2004 - 08/2003
2AngiotensinsIBA
02/2004 - 10/2002
2Polyethylene (Polythene)IBA
02/2004 - 10/2002
1OccludinIBA
04/2022
1Claudin-5IBA
04/2022
1CateninsIBA
01/2022
1Aminooxyacetic AcidIBA
01/2022
1CystathionineIBA
01/2022
1Caspase 3 (Caspase-3)IBA
01/2022
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
01/2022
1Plant ExtractsIBA
07/2020

Therapy/Procedure

4Therapeutics
07/2020 - 07/2005
1Chemoradiotherapy
09/2021